Kimon Hatza, Esq. of GrowthCounsel interviews Nikej N. Shah, M.D., CEO of Nirsum Laboratories about issues in Long-term opioid therapy: Unmet needs, Risks and Solutions with a new drug in Phase I testing with the FDA. Present drugs in use today are Bupremorphine, Methadone and Maltrexone.

Podcast: Play in new window | Download